Epinephrine producing pheochromocytoma. Is the secretory pattern decisive for the clinical manifestation?

Journal of Endocrinological Investigation

Volumn 27, Issue 7, 2004, Pages 691-694

  Lipsic, E ^a   Balazovjech, I ^a   Kosmalova V ^a   Makaiova I ^b   Dekret J ^a   Zanou, D F ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b St Elisabeth' Oncological Institute   (Slovakia)

Author keywords

Adrenal incidentaloma; Catecholamines; Hypertension; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ADRENALIN; CATECHOLAMINE DERIVATIVE; CORTICOSTEROID; DOPAMINE; IODINE 123; METADRENALIN;

ADRENAL CORTEX ADENOMA; ADRENAL SCINTISCANNING; ADRENAL TUMOR; ADRENALECTOMY; ADRENALIN URINE LEVEL; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOPAMINE URINE LEVEL; FEMALE; HUMAN; NEUROTRANSMITTER RELEASE; PATIENT REFERRAL; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; SCREENING; SYMPTOMATOLOGY;

EID: 5444236983     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347506     Document Type: Article

References (20)

1. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens 2002, 4: 62-72.
2. Balazovjech I. 25-years experience with diagnosis and therapy of pheochromocytoma. Vnit lek 1995, 41: 513-7.
3. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999, 141: 619-24.
4. Peppercorn PD, Grossman AB, Rezneck RH. Imaging of incidentally discovered adrenal masses. Clin Endocrinol (Oxf) 1998, 48: 379-88.
5. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995, 16: 460-84.
6. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85: 637-44.
7. Raff H, Findling JW. A physiological approach to diagnosis of Cushing syndrome. Ann Intern Med 2003, 138: 980-91.
8. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138: 424-30.
9. Yasunari K, Kohno M, Minami M, et al. A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol 2000, 36 (Suppl): S75-77.
10. Baxter MA, Hunter P, Thompson GR, London DR. Pheochromocytoma as a cause of hypotension. Clin Endocrinol (Oxf) 1992, 37: 304-6.
11. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, et al. Expression of neuropeptides and other neuroendocrine markers in human pheochromocytomas. Neuropeptides 1999, 33: 159-63.
12. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003, 24: 539-53.
13. Streeten DH, Anderson GH Jr. Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens 1996, 9: 760-9.
14. Lenders JW, Pacak K, Walther MM. Biochemical diagnosis of pheochromocytoma: which test is the best? JAMA 2002, 287: 1427-34.
15. Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci 2002, 970: 29-40.
16. Pacak K, Eisenhofer G, Carrasquillo Ja, Chen CC, Whatley M, Goldstein DS. Diagnostic localization of phechromocytoma: the coming of age of positron emission tomography. Ann N Y Acad Sci 2002, 970: 170-6.
17. Shulkin BL, Thomson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytoma: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 1999, 212: 35-41.
18. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001, 38: 6-8.
19. Sato T, Kobayashi K, Miura Y, Sakuma H, Yoshinaga K. High epinephrine content in the adrenal tumors from Sipple's syndrome. Tohoku J Exp Med 1975, 115: 115-9.
20. Januszewicz A, Neumann HP, Lon I et al. Incidence and clinical relevance of RET-proto-oncogene germline mutations in pheochromocytoma patients. J Hypertens 2000, 18: 1019-23.